...
首页> 外文期刊>International journal of immunopathology and pharmacology. >A comparative study of loratadine syrup and cyproheptadine HCL solution for treating perennial allergic rhinitis in taiwanese children aged 2-12 years
【24h】

A comparative study of loratadine syrup and cyproheptadine HCL solution for treating perennial allergic rhinitis in taiwanese children aged 2-12 years

机译:氯雷他定糖浆和赛庚啶盐酸盐溶液治疗2-12岁台湾儿童常年性变应性鼻炎的比较研究

获取原文
获取原文并翻译 | 示例

摘要

We assessed the efficacy of loratadine syrup compared with cyproheptadine HCl solution for treating children aged from 2 to 12 years with perennial allergic rhinitis (PAR) in Taiwan. Sixty children with mite-induced PAR were enrolled and randomly placed into two treatment groups: loratadine syrup or cyproheptadine HCl solution. Treatment efficacy and symptom changes from baseline to post-treatment were evaluated by total symptom scores and visual analogue scales (VAS) during a 2-week period. There were no differences in age, gender, height, or weight between the two groups. After 2 weeks of treatment, there was a significantly greater reduction in symptom scores in the loratadine group than in the cyproheptadine group (p<0.001). Clinical and subjective VAS showed significant differences in percentage changes from baseline between the loratadine and cyproheptadine groups at all time points (all p<0.001, in favor of loratadine). Clinical VAS change at week 1: 95.1 vs 11.3; subjective VAS change at week 1: 88.6 vs 13.6; clinical VAS change at week 2: 125.5 vs 18.3; subjective VAS change at week 2: 101.4 vs 7.1. Thus, loratadine was superior to cyproheptadine for alleviating both nasal and non-nasal symptoms of perennial allergic rhinitis in Taiwanese children aged 2-12 years.
机译:我们评估了氯雷他定糖浆与盐酸赛庚啶溶液相比在台湾治疗2至12岁常年性变应性鼻炎(PAR)的儿童的疗效。招募了60名患有螨虫诱发的PAR的儿童,并将其随机分为两个治疗组:氯雷他定糖浆或赛庚啶盐酸盐溶液。在2周的时间内,通过总症状评分和视觉模拟量表(VAS)评估从基线到治疗后的治疗功效和症状变化。两组之间的年龄,性别,身高或体重均无差异。治疗2周后,氯雷他定组的症状评分明显降低,而赛庚啶组的症状评分明显降低(p <0.001)。临床和主观VAS显示在所有时间点,氯雷他定和赛庚啶组之间的基线变化百分比存在显着差异(所有p <0.001,赞成氯雷他定)。第1周的临床VAS变化:95.1 vs 11.3;第1周的主观VAS变化:88.6 vs 13.6;第2周的临床VAS变化:125.5 vs 18.3;第2周的主观VAS变化:101.4与7.1。因此,在缓解2至12岁台湾儿童常年性变应性鼻炎的鼻和非鼻症状方面,氯雷他定优于赛庚啶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号